French pharmaceutical company said drug could treat COVID-19 patients after promising test results

19 March 2020
227 Views

A leading French pharmaceutical company said it could potentially treat 300,000 COVID-19 patients with the anti-malarial drug Plaquenil after what it described as “promising” test results.

Sanofi said it was ready to offer France millions of doses of Plaquenil, a spokesperson for the laboratory told AFP, adding that the group was ready to work with French health authorities “to confirm these results.”

The study on 24 patients with coronavirus using Plaquenil, a hydroxychloroquine molecule, which has also been used for decades for the treatment of autoimmune diseases like lupus or rheumatoid arthritis.

Six days after the start of taking Plaquenil, the virus had disappeared in three-quarters of those treated, said Professor Didier Raoult, who is director of the Institut Hospitalo-Universitaire de Marseille.

The French government said the clinical trials were “promising” and would be extended to more patients.

source: arabnews.com

You may be interested

Telegraph: When coronavirus ends, Greece is the first spot to visit
GREECE
shares62 views
GREECE
shares62 views

Telegraph: When coronavirus ends, Greece is the first spot to visit

Panos - Apr 09, 2020

Telegraph’s digital traveller writer Oliver Smith says Greece will be his first holiday destination after the coronavirus crisis ends. In…

The Biggest Financial Contributors To The WHO
GREECE
shares54 views
GREECE
shares54 views

The Biggest Financial Contributors To The WHO

Panos - Apr 09, 2020

As the slow initial U.S. response to the COVID-19 pandemic comes under increasing scrutiny, President Trump has denied any responsibility…

Christine Lagarde: The ECB helps firms & families
FINANCE
shares61 views
FINANCE
shares61 views

Christine Lagarde: The ECB helps firms & families

Panos - Apr 09, 2020

“If not all countries are cured, the others will suffer. Solidarity is in fact self-interest” By Christine Lagarde, President of…

Leave a Comment

Your email address will not be published.